Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Australia Has the Strongest Presence of These Innovative Products, But Competitors Are Increasingly Focusing on China, According to Findings from Decision Resources Group
BURLINGTON, Mass., July 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the Asia Pacific market for transcatheter embolization and occlusion (TEO) devices-including Australia, China, South Korea and India-is a dynamic and fast-growing market, driven by the launch of novel products such as interventional neuroradiology (INR) flow-diverting devices and radioembolization spheres. However, the adoption and availability of these products varies widely by country.
Other key findings from Decision Resources Group's coverage of the Asia Pacific TEO device market:
- INR flow-diverting devices in Australia: Australian physicians in particular have embraced INR flow-diverting devices, and all four major companies in the market have products approved for sale in the country.
- Radioembolization spheres in Australia: Australia also represented the largest market for radioembolization spheres in the region in 2013 given that Sirtex Medical, one of two companies globally that offers these products, is an Australian manufacturer. The company also has its products approved in India and South Korea and is currently investigating Chinese approval.
- Liver cancer rates in China and South Korea: China and South Korea offer especially strong potential for competitors in the radioembolization sphere space-and in the embolization particle market in general-given the particularly high incidence of liver cancer in the countries, which can be treated using these products.
Comments from Decision Resources Group Senior Analyst Sean Messenger:
- "Although no INR flow-diverting devices are currently available in China, Covidien's Pipeline device is expected to be available by the end of this year. MicroPort Medical, a local Chinese competitor, will also likely get approval for its Tubridge device in the next few years. MicroPort Medical is unique in that it does not offer INR coils, unlike the other competitors in the INR flow-diverting device space. The company does, however, have experience in the neurovascular space with its Apollo and WILLIS stents."
- "Sirtex Medical has traditionally had little competition in the Asia Pacific radioembolization sphere market because TheraSphere, the other main radioembolization product, was not heavily promoted in the region. However, since the TheraSphere technology was acquired from Nordion by BTG, we will likely see a growing presence of the product in the region. For example, Nordion had been working with SciClone Pharmaceuticals to gain approval in China, and BTG's prior experience working with SciClone for approval of its DC Bead will likely speed this process along."
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO
©2012 PR Newswire. All Rights Reserved.